Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501014 | 0.90 | RXRA (0.41) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL3501076 | 0.88 | NPC1 (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL3500997 | 0.85 | RAB9A (0.41) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL3500534 | 0.84 | P2RY14 (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL3501258 | 0.84 | NPC1 (0.37) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL3501370 | 0.83 | CYP4F2 (0.41) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL13283574 | 0.82 | NPC1 (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL13312302 | 0.82 | HDAC3 (0.42) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL3498760 | 0.82 | CYP4F2 (0.42) | ADORA3CYP4F2CYP4A11RXRARXRB | |
| SCHEMBL3501950 | 0.81 | NPC1 (0.35) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2108644-B1 | N-(Methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-8673940-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20120309791-A1 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2108644-A1 | N-(methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins | AC Immune S.A. (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-2102165-A2 | N-(METHYL)-1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC Immune S.A. (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008061795-A2 | N- (METHYL) -1H- PYRAZOL- 3 -AMINE, N- (METHYL) -PYRIDIN-2-AMINE AND N- (METHYL) -THIAZ0L-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | PSEN2, APP, PSEN1 | ADORA3 175/4885CYP4F2 2625/4885CYP4A11 2211/4885 |
| US-20120309791-A1 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | APP, PSEN2, PSEN1 | ADORA3 2296/4885CYP4F2 3132/4885CYP4A11 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.